Calixar
Lyon
About Calixar
Calixar provides a comprehensive range of services focused exclusively on membrane proteins (which account for over 70 per cent of therapeutic targets), including: identification, production, extraction, purification, stabilization and crystallization. Its patented technology, which has already been validated on a score of targets (including GPCR receptors, ionic channels, transporters and viral proteins), can isolate and purify any type of membrane protein in its complete native form, which remains stable in solution. The company’s services are aimed at private and public research establishments interested in the development of antibodies, especially those for therapeutic applications, drug discovery (screening and drug design) and vaccines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.2M
- Funding stage: M&A
- Last round: Series B (Feb 2015)
- Website: calixar.com
- Phone: 33437652939
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/calixar-2924664 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.